• EMA’s CHMP recommended expanding TECVAYLI (teclistamab) with daratumumab for adults with relapsed or refractory multiple myeloma.
• Label extension targets patients with at least one prior therapy, positioning the regimen for use as early as second line.
• Phase 3 MajesTEC-3 showed a progression or death risk cut of 83.4% versus standard care; 3-year survival was 83.3%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief on June 26, 2026, and is solely responsible for the information contained therein.